Serghini M, Haddad W, Jeddi H, Karoui S, Ben Mustapha N, Kallel L, Fekih M, Matri S, Boubaker J, Filali A
Service de Gastro-enterologie, A. Hopital la Rabta, Tunis.
Tunis Med. 2012 Feb;90(2):101-7.
Adalimumab is the first subcutaneously self administered fully human anti-TNFa.
To determine efficacy and safety of Adalimumab therapy in Crohn disease.
Literature review.
Adalimumab has been evaluated for its effect in inducing and maintaining remission and its steroid-sparing effect of refractory Crohn's disease. In addition, it offers a significant treatment option in patients who have lost response to or become intolerant to Infliximab. Results also suggest efficacy of Adalimumab in fistulising Crohn's disease but more studies are needed. Adalimumab was well tolerated and studies show that all anti-TNF inhibitors have similar safety profiles.
阿达木单抗是首个皮下自我注射的全人源抗TNFα药物。
确定阿达木单抗治疗克罗恩病的疗效和安全性。
文献综述。
已对阿达木单抗诱导和维持缓解的效果及其对难治性克罗恩病的激素节省作用进行了评估。此外，对于对英夫利昔单抗失去反应或不耐受的患者，它提供了一种重要的治疗选择。结果还提示阿达木单抗在克罗恩病肛瘘治疗中有效，但仍需更多研究。阿达木单抗耐受性良好，研究表明所有抗TNF抑制剂具有相似的安全性。
